Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound’s Drug Discovery and Repurposing for HBV Therapy
Open Access
- 16 March 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (3) , 419
Abstract
Hepatitis B virus (HBV) is an important global public health issue. The World Health Organization (WHO) 2024 Global Hepatitis Report estimated that the global prevalence of people living with HBV infection is 254 million, with an estimated prevalence incidence of 1.2 million new HBV infections yearly. Previous studies have shown that natural compounds have antiviral inhibition potentials. In silico methods such as molecular docking, virtual screening, pharmacophore modeling, quantitative structure–activity relationship (QSAR), and molecular dynamic simulations have been successfully applied in identifying bioactive compounds with strong binding energies in HBV treatment targets. The COVID-19 pandemic necessitated the importance of repurposing already approved drugs using in silico methods. This study is aimed at unveiling the benefits of in silico techniques as a potential alternative in natural compounds’ drug discovery and repurposing for HBV therapy. Relevant articles from PubMed, Google Scholar, and Web of Science were retrieved and analyzed. Furthermore, this study comprehensively reviewed the literature containing identified bioactive compounds with strong inhibition of essential HBV proteins. Notably, hesperidin, quercetin, kaempferol, myricetin, and flavonoids have shown strong binding energies for hepatitis B surface antigen (HBsAg). The investigation reveals that in silico drug discovery methods offer an understanding of the mechanisms of action, reveal previously overlooked viral targets (including PreS1 Domain of HBsAg and cccDNA (Covalently Closed Circular DNA) regulators, and facilitate the creation of specific inhibitors. The integration of in silico, in vitro, and in vivo techniques is essential for the discovery of new drugs for HBV therapy. The insights further highlight the importance of natural compounds and in silico methods as targets in drug discovery for HBV therapy. Moreover, the combination of natural compounds, an in silico approach, and drug repurposing improves the chances of personalized and precision medicine in HBV treatment. Therefore, we recommend drug repurposing strategies that combine in vitro, in vivo, and in silico approaches to facilitate the discovery of effective HBV drugs.Keywords
This publication has 176 references indexed in Scilit:
- Glycyrrhizin and its derivatives: an emerging secondary metabolite arsenal of Glycyrrhiza glabraMedicinal Chemistry Research, 2025
- Antiviral Potential and In Silico Insights of Polyphenols as Sustainable Phytopharmaceuticals: A Comprehensive ReviewChemistry & Biodiversity, 2024
- Potential role of microRNAs in personalized medicine against hepatitis: a futuristic approachArchives of Virology, 2024
- Computational Pharmacokinetics Report, ADMET Study and Conceptual DFT‐Based Estimation of the Chemical Reactivity Properties of Marine CyclopeptidesChemistryOpen, 2021
- Andrographis paniculata (Burm. F) Wall ex Nees: Antiviral propertiesPhytotherapy Research, 2021
- Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus InfectionsChemMedChem, 2021
- Antiviral activity of berberineArchives of Virology, 2020
- Prophylactic vaccination against hepatitis B: achievements, challenges and perspectivesMedical Microbiology and Immunology, 2014
- QSAR and pharmacophore modeling of indole-based C-3 pyridone compounds as HCV NS5B polymerase inhibitors utilizing computed molecular descriptorsMedicinal Chemistry Research, 2014
- Predicting the Biological Activities Through QSAR Analysis and Docking-Based Scoring2012